Company Reports Advancements in Neurology-Focused Pipeline and Anticipates Multiple Products in  Phase 2 or Later Stage Development this Year Conference Call at 4:30 pm ET Today BURNABY, British Columbia , May 07, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. ...

BURNABY, British Columbia , April 30, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2019 financial and operating results after the close of U.S. ...

BURNABY, British Columbia , April 24, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone , Xenon's Chief Executive Officer, will present a corporate update at the Bloom Burton & Co. ...

Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 Global XEN1101 Phase 2b Clinical Trial Underway with Data Anticipated in Second Half of 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia , March 06, 2019 (GLOBE NEWSWIRE) -- Xenon ...

BURNABY, British Columbia , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2018 financial and operating results after the close of U.S. financial markets on Wednesday, March 6, 2019 . ...

Behind the Seizure™ Program Expansion Helps Speed the Diagnosis  of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures — Stoke Therapeutics and Xenon Pharmaceuticals Join  Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing  Program for Children Up to 60 ...

FDA Grants Rare Pediatric Disease Designation to XEN007 for Alternating Hemiplegia of Childhood (AHC); Xenon Eligible to Apply for Priority Review Voucher IND for XEN1101 Accepted; Site Selection and Patient Enrollment Underway in Canada and the United States for XEN1101 Phase 2b Clinical Trial ...

Innovative Product Pipeline Includes Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 BURNABY, British Columbia , Jan. 06, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided ...